Form 4: DexCom Director Steven Altman Receives RSU Grant
Statement of Changes in Beneficial Ownership
Director Steven R. Altman was granted 5,565 restricted stock units as part of his equity compensation package.
Summary
- Director Steven R. Altman received an award of 5,565 restricted stock units (RSUs) on May 28, 2026.
- The RSUs represent a contingent right to receive one share of DexCom, Inc. common stock per unit upon settlement.
- The award is scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the date of the 2027 Annual Meeting of Stockholders.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- Equity-based compensation aligns the interests of the director with those of long-term shareholders.
Negatives
- None identified; this is a standard director compensation event.
Risks
- None identified; this is a standard director compensation event.
Future Outlook
The RSUs will vest on the earlier of May 28, 2027, or the date of the 2027 Annual Meeting of Stockholders.
Industry Context
StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the medical device industry to ensure director retention and alignment with shareholder value creation.
Comparison to Industry Standards
- The grant of RSUs to non-employee directors is consistent with compensation practices at peer medical technology companies such as Abbott Laboratories and Medtronic.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Steven Altman filed a Power of Attorney authorizing specific company officers to handle SEC filings on his behalf. | 05/12/2025 | Standard administrative procedure to ensure timely compliance with SEC reporting requirements. |
Stakeholder Impact
- Minimal impact on shareholders; reflects standard director compensation.
Next Steps
- Vesting of the RSU award on the earlier of May 28, 2027, or the 2027 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 05/12/2025 | Date of Power of Attorney execution. |
| 05/28/2026 | Grant date of the RSU award. |
| 06/01/2026 | Filing date of the Form 4. |
Keywords
DexCom, DXCM, Director Compensation, Restricted Stock Units, Insider Transaction, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.